Radnet, Inc. Announces Date Of Its Fourth Quarter 2023 Financial Results Conference Call


(MENAFN- GlobeNewsWire - Nasdaq) LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its fourth quarter 2023 financial results on Friday, March 1, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors are invited to listen to RadNet's conference call by dialing 844-826-3035 . International callers can dial 412-317-5195 . There will also be simultaneous and archived webcasts available at /starthere?ei=1657167&tp_key=5b49295358 . An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10186577 .

About RadNet, Inc .
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has over 9,000 employees. For more information, visit

CONTACTS:

RadNet, Inc.
Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800


MENAFN13022024004107003653ID1107845600


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.